Prospects for developing an effective vaccine against ocular herpes simplex virus infection

Current Eye Research

Volumn 30, Issue 11, 2005, Pages 929-942

  Koelle, David M ^a,b   Ghiasi, Homayon ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

Author keywords

DNA; Eye; Glycoprotein; Immunity; Immunization

Indexed keywords

DNA VACCINE; HERPES SIMPLEX VACCINE; LIVE VACCINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; VIRUS VACCINE; VIRUS VECTOR;

CLINICAL TRIAL; EYE INFECTION; GENE; GENE THERAPY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; INFECTION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; SHORT SURVEY; STEREOTYPY; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS SHEDDING;

ANIMALS; GENETIC VECTORS; HUMANS; KERATITIS, HERPETIC; TECHNOLOGY, PHARMACEUTICAL; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 31544482423     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680500313153     Document Type: Short Survey

References (157)

1. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20:1-13.
2. Adelson ME, Feola M, Trama J, Tilton RC, Mordechai E. Simultaneous detection of herpes simplex virus types 1 and 2 by real-time PCR and Pyrosequencing. J Clin Virol. 2005;33:25-34.
3. Oh JO, Kimura SJ, Ostler HB, Dawson CR, Smolin G. Oculogenital transmission of type 2 herpes simplex virus in adults. Surv Ophthalmol. 1976;21:106-109.
4. Dawson CR, Togni B. Herpes simplex eye infections: clinical manifestations, pathogenesis and management. Surv Ophthalmol. 1976;21:121-135.
5. Pavan-Langston D. Ocular viral infections. Med Clin North Am. 1983;67:973-990.
6. Corey L. The current trend in genital herpes. Progress in prevention. Sex Transm Dis. 1994;21:S38-S44.
7. Liesegang TJ. Classification of herpes simplex virus keratitis and anterior uveitis. Cornea. 1999;18:127-143.
8. Dix RD. Prospects for a vaccine against herpes simplex virus types 1 and 2. Prog Med Virol. 1987;34:89-128.
9. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis. 2003;30:797-800.
10. Auslander BA, Biro FM, Rosenthal SL. Genital herpes in adolescents. Semin Pediatr Infect Dis. 2005;16:24-30.
11. Singh AE, Romanowski B, Wong T, et al. Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinics. Sex Transm Dis. 2005;32:95-100.
12. Dawson CR. Ocular herpes simplex virus infections. Clin Dermatol 1984;2:56-66.
13. Barron BA, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1871-1882.
14. Wilhelmus KR, Dawson CR, Barron BA, et al. Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Herpetic Eye Disease Study Group. Br J Ophthalmol. 1996;80:969-972.
15. Hill TJ. Ocular pathogenicity of herpes simplex virus. Curr Eye Res. 1987;6:1-7.
16. Binder PS. A review of the treatment of ocular herpes simplex infections in the neonate and immunocompromised host. Cornea. 1984;3:178-182.
17. Streilein JW, Dana MR, Ksander BR. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol Today. 1997;18:443-449.
18. Thomas J, Rouse BT. Immunopathogenesis of herpetic ocular disease. Immunol Res 1997;16:375-386.
19. Branco BC, Gaudio PA, Margolis TP. Epidemiology and molecular analysis of herpes simplex keratitis requiring primary penetrating keratoplasty. Br J Ophthalmol. 2004;88:1285-1288.
20. Dix RD. Pathogenesis of herpes simplex ocular disease. Philadelphia: Lippincott Williams & Wilkins;2002:1-21.
21. Roizman B, Sears AE. An inquiry into the mechanisms of herpes simplex virus latency. Annu Rev Microbiol. 1987;41:543-571.
22. Stevens JG. Human herpesviruses: a consideration of the latent state. Microbiol Rev. 1989;53:318-332.
23. Gordon YJ. Pathogenesis and latency of herpes simplex virus type 1 (HSV-1): an ophthalmologist's view of the eye as a model for the study of the virus-host relationship. Adv Exp Med Biol 1990;278:205-209.
24. Steiner I. Human herpes viruses latent infection in the nervous system. Immunol Rev. 1996;152:157-173.
25. Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci. 2005;46:241-247.
26. Metcalf JF, Kaufman HE. Herpetic stromal keratitis-evidence for cell-mediated immunopathogenesis. Am J Ophthalmol. 1976;82:827-834.
27. Hendricks RL, Tumpey TM. Contribution of virus and immune factors to herpes simplex virus type I-induced corneal pathology. Invest Ophthalmol Vis Sci. 1990;31:1929-1939.
28. Banerjee K, Deshpande S, Zheng M, Kumaraguru U, Schoenberger SP, Rouse BT. Herpetic stromal keratitis in the absence of viral antigen recognition. Cell Immunol. 2002;219:108-18.
29. Zhao ZS, Granucci F, Yeh L, Schaffer PA, Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science. 1998;279:1344-1347.
30. Huster KM, Panoutsakopoulou V, Prince K, Sanchirico ME, Cantor H. T cell-dependent and -independent pathways to tissue destruction following herpes simplex virus-1 infection. Eur J Immunol. 2002;32:1414-1419.
31. Brown DC, Nesburn AB, Nauheim JS, Pavan-Langston D, Kaufman HE. Recurrent herpes simplex conjunctivitis. Arch Ophthalmol. 1968;79:733-735.
32. Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 1994;343:1460-1463.
33. Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997;176:1129-1134.
34. Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol. 2003;121:108-112.
35. Uchoa UB, Rezende RA, Carrasco MA, Rapuano CJ, Laibson PR, Cohen EJ. Long-term acyclovir use to prevent recurrent ocular herpes simplex virus infection. Arch Ophthalmol. 2003;121:1702-1704.
36. A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. The Herpetic Eye Disease Study Group. Arch Ophthalmol. 1997;115:703-712.
37. A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic Eye Disease Study Group. Arch Ophthalmol. 1996;114:1065-1072.
38. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Herpetic Eye Disease Study Group. Arch Ophthalmol. 2000;118:1030-1036.
39. Corey L, Spear PG. Infections with herpes simplex viruses (1). N Engl J Med. 1986;314:686-691.
40. Kieff E, Hoyer B, Bachenheimer S, Roizman B. Genetic relatedness of type 1 and type 2 herpes simplex viruses. J Virol. 1972;9:738-745.
41. McGeoch DJ, Cook S, Dolan A, Jamieson FE, Telford EA. Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J Mol Biol. 1995;247:443-458.
42. Nesburn AB, Burke RL, Ghiasi H, Slanina S, Bahri S, Wechsler SL. Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J Virol. 1994;68:5084-5092.
43. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652-1661.
44. Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis. 1990;161:653-660.
45. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med. 1987;316:1444-1449.
46. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999;282:331-340.
47. Cook ML, Bastone VB, Stevens JG. Evidence that neurons harbor latent herpes simplex virus. Infect Immun. 1974;9:946-951.
48. Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT. RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science. 1987;235:1056-1059.
49. Rock DL, Nesburn AB, Ghiasi H, et al. Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J Virol. 1987;61:3820-3826.
50. Stanberry LR. Herpesvirus latency and recurrence. Prog Med Virol. 1986;33:61-77.
51. Hill JM, Gebhardt BM, Wen R, et al. Quantitation of herpes simplex virus type 1 DNA and latency-associated transcripts in rabbit trigeminal ganglia demonstrates a stable reservoir of viral nucleic acids during latency. J Virol. 1996;70:3137-3141.
52. Hill JM, Sedarati F, Javier RT, Wagner EK, Stevens JG. Herpes simplex virus latent phase transcription facilitates in vivo reactivation. Virology. 1990;174:117-125.
53. Feldman LT, Ellison AR, Voytek CC, Yang L, Krause P, Margolis TP. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci USA. 2002;99:978-983.
54. Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity. 2003;18:593-603.
55. Robert PY, Adenis JP, Denis F, Alain S, Ranger-Rogez S. Herpes simplex virus DNA in corneal transplants: prospective study of 38 recipients. J Med Virol. 2003;71:69-74.
56. Remeijer L, Maertzdorf J, Doornenbal P, Verjans GM, Osterhaus AD. Herpes simplex virus 1 transmission through corneal transplantation. Lancet. 2001;357:442
57. O'Brien WJ, Tsao LS, Taylor JL. Tissue-specific accumulation of latency-associated transcripts in herpes virus-infected rabbits. Invest Ophthalmol Vis Sci. 1998;39:1847-1853.
58. Wechsler SL, Nesburn AB, Watson R, Slanina SM, Ghiasi H. Fine mapping of the latency-related gene of herpes simplex virus type 1: alternative splicing produces distinct latency-related RNAs containing open reading frames. J Virol. 1988;62:4051-4058.
59. Wechsler SL, Nesburn AB, Watson R, Slanina S, Ghiasi H. Fine mapping of the major latency-related RNA of herpes simplex virus type 1 in humans. J Gen Virol. 1988;69:3101-3106.
60. Wagner EK, Flanagan WM, Devi-Rao G, et al. The herpes simplex virus latency-associated transcript is spliced during the latent phase of infection. J Virol. 1988;62:4577-4585.
61. Fraser NW, Spivack JG, Wroblewska Z, et al. A review of the molecular mechanism of HSV-1 latency. Curr Eye Res. 1991;10:1-13.
62. Farrell MJ, Hill JM, Margolis TP, Stevens JG, Wagner EK, Feldman LT. The herpes simplex virus type 1 reactivation function lies outside the latency-associated transcript open reading frame ORF-2. J Virol. 1993;67:3653-3655.
63. Bloom DC, Hill JM, Devi-Rao G, Wagner EK, Feldman LT, Stevens JG. A 348-base-pair region in the latency-associated transcript facilitates herpes simplex virus type 1 reactivation. J Virol. 1996;70:2249-2259.
64. Perng GC, Jones C, Ciacci-Zanella J, et al. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science. 2000;287:1500-1503.
65. Thompson RL, Sawtell NM. HSV latency-associated transcript and neuronal apoptosis. Science. 2000;289:1651.
66. Fink DJ, DeLuca NA, Goins WF, Glorioso JC. Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci. 1996;19:265-287.
67. Goss JR, Goins WF, Lacomis D, Mata M, Glorioso JC, Fink DJ. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes. 2002;51:2227-2232.
68. Osorio Y, Ghiasi H. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes. J Virol. 2003;77:5774-5783.
69. Osorio Y, Sharifi BG, Perng GC, Ghiasi NS, Ghiasi H. The role of TH1 and TH2 cytokines in HSV-1-induced corneal scarring. Ocular Immunology and Inflammation. 2003;10:105-116.
70. Osorio Y, Ghiasi H. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge. J Virol. 2005;79:3297-3308.
71. McGeoch DJ, Dalrymple MA, Davison AJ, et al. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol. 1988;69:1531-1574.
72. Ghiasi H, Slanina S, Nesburn AB, Wechsler SL. Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K. J Virol. 1994;68:2347-2354.
73. Ghiasi H, Kaiwar R, Nesburn AB, Slanina S, Wechsler SL. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. J Virol. 1994;68:2118-2126.
74. Ghiasi H, Kaiwar R, Slanina S, Nesburn AB, Wechsler SL. Expression and characterization of baculovirus expressed herpes simplex virus type 1 glycoprotein L. Arch Virol. 1994;138:199-212.
75. Ghiasi H, Bahri S, Nesburn AB, Wechsler SL. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins. Invest Ophthalmol Vis Sci. 1995;36:1352-1360.
76. Spear PG, Sarmiento M, Manservigi R. The structural proteins and glycoproteins of herpesviruses: a review. IARC Sci Publ. 1978;24:157-167.
77. Jennings SR, Lippe PA, Pauza KJ, Spear PG, Pereira L, Tevethia SS. Kinetics of expression of herpes simplex virus type 1-specific glycoprotein species on the surfaces of infected murine, simian, and human cells: flow cytometric analysis. J Virol. 1987;61:104-112.
78. Johnson DC, Feenstra V. Identification of a novel herpes simplex virus type 1-induced glycoprotein which complexes with gE and binds immunoglobulin. J Virol. 1987;61:2208-2216.
79. Friedman HM, Glorioso JC, Cohen GH, Hastings JC, Harris SL, Eisenberg RJ. Binding of complement component C3b to glycoprotein gC of herpes simplex virus type 1: mapping of gC-binding sites and demonstration of conserved C3b binding in low-passage clinical isolates. J Virol. 1986;60:470-475.
80. Lin X, Lubinski JM, Friedman HM. Immunization strategies to block the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol. 2004;78:2562-2571.
81. Judson KA, Lubinski JM, Jiang M, et al. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection. J Virol. 2003;77:12639-12645.
82. Zhao ZS, Granucci F, Yeh L, Schaffer PA, Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science. 1998;279:1344-1347.
83. Aurelian L, Ono F, Burnett J. Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J. 2003;9:1.
84. Burke RL. Contemporary approaches to vaccination against herpes simplex virus. Curr Top Microbiol Immunol. 1992;179:137-158.
85. Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol. 2004;6:401-410.
86. Ghiasi H, Kaiwar R, Nesburn AB, Slanina S, Wechsler SL. Baculovirus-expressed glycoprotein E (gE) of herpes simplex virus type- 1 (HSV-1) protects mice against lethal intraperitoneal and lethal ocular HSV-1 challenge. Virology. 1992;188:469-476.
87. Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL. Baculovirus expressed herpes simplex virus type 1 glycoprotein C protects mice from lethal HSV-1 infection. Antiviral Res. 1992;18:291-302.
88. Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL. Expression of herpes simplex virus type 1 glycoprotein I in baculovirus: preliminary biochemical characterization and protection studies. J Virol. 1992;66:2505-2509.
89. Ghiasi H, Nesburn AB, Kaiwar R, Wechsler SL. Immunoselection of recombinant baculoviruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D. Arch Virol. 1991;121:163-178.
90. Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL. Expression of herpes simplex virus type 1 glycoprotein B in insect cells. Initial analysis of its biochemical and immunological properties. Virus Res. 1992;22:25-39.
91. Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL. Baculovirus-expressed glycoprotein G of herpes simplex virus type 1 partially protects vaccinated mice against lethal HSV-1 challenge. Virology. 1992;190:233-239.
92. Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL. Baculovirus-expressed glycoprotein H of herpes simplex virus type 1 (HSV-1) induces neutralizing antibody and delayed type hypersensitivity responses, but does not protect immunized mice against lethal HSV-1 challenge. J Gen Virol. 1992;73:719-722.
93. Ghiasi H, Nesburn AB, Cai S, Wechsler SL. The US5 open reading frame of herpes simplex virus type 1 does encode a glycoprotein (gJ). Intervirology. 1998;41:91-97.
94. Ghiasi H, Cai S, Slanina S, Nesburn AB, Wechsler SL. Nonneutralizing antibody against the glycoprotein K of herpes simplex virus type-1 exacerbates herpes simplex virus type-1-induced corneal scarring in various virus-mouse strain combinations. Invest Ophthalmol Vis Sci. 1997;38:1213-1221.
95. Ghiasi H, Cai S, Nesburn AB, Wechsler SL. Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection. Virology. 1996;224:330-333.
96. Eisenberg RJ, Cerini CP, Heilman CJ, et al. Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge. J Virol. 1985;56:1014-1017.
97. Rosenthal KS, Mao H, Horne WI, Wright C, Zimmerman D. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 1999;17:535-542.
98. BenMohamed L, Bertrand G, McNamara CD, et al. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J Virol. 2003;77:9463-9473.
99. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203-209.
100. Oehen S, Hengartner H, Zinkernagel RM. Vaccination for disease. Science 1991;251:195-198.
101. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis. 1988;158:602-614.
102. Irie H, Harada Y, Kataoka M, et al. Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine. J Virol. 1992;66:2428-2434.
103. Roizman B, Jenkins FJ. Genetic engineering of novel genomes of large DNA viruses. Science. 1985;229:1208-1214.
104. Brockman MA, Knipe DM. Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J Virol 2002;76:3678-3687.
105. Javier RT, Sedarati F, Stevens JG. Two avirulent herpes simplex viruses generate lethal recombinants in vivo. Science. 1986;234:746-748.
106. Norberg P, Bergstrom T, Rekabdar E, Lindh M, Liljeqvist JA. Phylogenetic analysis of clinical herpes simplex virus type 1 isolates identified three genetic groups and recombinant viruses. J Virol. 2004;78:10755-10764.
107. Lausch RN, Monteiro C, Kleinschrodt WR, Oakes JE. Superiority of antibody versus delayed hypersensitivity in clearance of HSV-1 from eye. Invest Ophthalmol Vis Sci. 1987;28:565-570.
108. Bonina L, Nash AA, Arena A, Leung KN, Wildy P. T cell-macrophage interaction in arginase-mediated resistance to herpes simplex virus. Virus Res. 1984;1:501-505.
109. Nash AA, Field HJ, Quartey-Papafio R. Cell-mediated immunity in herpes simplex virus-infected mice: induction, characterization and antiviral effects of delayed type hypersensitivity. J Gen Virol. 1980;48:351-357.
110. Kohl S. The role of antibody in herpes simplex virus infection in humans. Curr Top Microbiol Immunol. 1992;179:75-88.
111. Daheshia M, Kuklin N, Manickan E, Chun S, Rouse BT. Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines. Vaccine. 1998;16:1103-1110.
112. Ulmer JB, Fu TM, Deck RR, et al. Protective CD4+ and CD8+T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol. 1998;72:5648-5653.
113. Shata MT, Hone DM. Vaccination with a shigella DNA vaccine vector induces antigen-specific cd8(+) t cells and antiviral protective immunity. J Virol. 2001;75:9665-9670.
114. Wang R, Epstein J, Baraceros FM, et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA. 2001;98:10817-10822.
115. Xing Z, Zganiacz A, Wang J, Sharma SK. Enhanced protection against fatal mycobacterial infection in SCID beige mice by reshaping innate immunity with IFN-gamma transgene. J Immunol. 2001;167:375-383.
116. Cafaro A, Titti F, Fracasso C, et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine. 2001;19:2862-2877.
117. Ghiasi H, Cai S, Slanina S, Nesburn AB, Wechsler SL. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Res. 1995;28:147-157.
118. Martins LP, Lau LL, Asano MS, Ahmed R. DNA vaccination against persistent viral infection. J Virol. 1995;69:2574-2582.
119. Yokoyama M, Zhang J, Whitton JL. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J Virol. 1995;69:2684-2688.
120. Norton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J Immunol. 1999;163:6378-6385.
121. Norton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci USA. 1999;96:1553-1558.
122. Osorio Y, Cohen J, Ghiasi H. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenie DNA vaccines. Invest Ophthalmol Vis Sci. 2004;45:506-514.
123. Sedegah M, Brice GT, Rogers WO, et al. Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T- cell populations. Infect Immun. 2002;70:3493-3499.
124. Bernstein DI, Aoki FY, Tyring SK, et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis. 2005;40:1271-81.
125. Berman PW, Dowbenko D, Lasky LA, Simonsen CC. Detection of antibodies to herpes simplex virus with a continuous cell line expressing cloned glycoprotein D. Science 1983;222:524-527.
126. Cantin EM, Eberle R, Baldick JL, et al. Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection. Proc Natl Acad Sci USA 1987;84:5908-5912.
127. Kino Y, Nozaki C, Nakatake H, Mizuno K, Mori R. Immunogenicity of herpes simplex virus glycoprotein gB-1-related protein produced in yeast. Vaccine. 1989;7:155-160.
128. Hanke T, Graham FL, Lulitanond V, Johnson DC. Herpes simplex virus IgG Fc receptors induced using recombinant adenovirus vectors expressing glycoproteins E and I. Virology. 1990;177:437-444.
129. Stanberry LR, Myers MG, Stephanopoulos DE, Burke RL. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy. J Gen Virol. 1989;70:3177-3185.
130. Cremer KJ, Mackett M, Wohlenberg C, Notkins AL, Moss B. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science. 1985;228:737-740.
131. Ghiasi H, Nesburn AB, Wechsler SL. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine. 1996;14:107-112.
132. Blacklaws BA, Nash AA, Darby G. Specificity of the immune response of mice to herpes simplex virus glycoproteins B and D constitutively expressed on L cell lines. J Gen Virol. 1987;68:1103-1114.
133. Ghiasi H, Hofman FM, Wallner K, et al. Corneal macrophage infiltrates following ocular herpes simplex virus type 1 challenge vary in BALB/c mice vaccinated with different vaccines. Vaccine. 2000;19:1266-1273.
134. Ghiasi H, Nesburn AB, Wechsler SL. Cell surface expression of herpes simplex virus type 1 glycoprotein H in recombinant baculovirus-infected cells. Virology. 1991;185:187-194.
135. Ghiasi H, Wechsler SL, Cai S, Nesburn AB, Hofman FM. The role of neutralizing antibody and T-helper subtypes in protection and pathogenesis of vaccinated mice following ocular HSV-1 challenge. Immunology. 1998;95:352-359.
136. Ghiasi H, Hofman FM, Cai S, Perng GC, Nesburn AB, Wechsler SL. Vaccination with different HSV-1 glycoproteins induces different patterns of ocular cytokine responses following HSV-1 challenge of vaccinated mice. Vaccine. 1999;17:2576-2582.
137. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis. 1987;155:914-920.
138. Ho RJ, Burke RL, Merigan TC. Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs. Vaccine. 1992;10:209-213.
139. Burke RL. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. Rev Infect Dis. 1991;13:S906-S911.
140. Frank SB. Formolised herpes virus therapy and the neutralizing substance in herpes simplex. J Invest Dermatol. 1938;1:267-282.
141. Kern AB, Schiff BL. Vaccine therapy in recurrent herpes simplex. Arch Dermatol. 1964;89:844-5.
142. Dundarov S, Andonov P, Bakalov B, Nechev K, Tomov C. Immunotherapy with inactivated polyvalent herpes vaccines. Dev Biol Stand. 1982;52:351-358.
143. Kavaklova L, Dundarov S, Andonov P, Bakalov B, Dundarova D, Brodvarova I. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines. Acta Virol. 1986;30:402-410.
144. Skinner GR, Williams DR, Buchan A, Whitney J, Harding M, Bodfish K. Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 herpes simplex virus infection. Med Microbiol Immunol (Berl). 1978;166:119-132.
145. Cappel R, Sprecher S, De Cuyper F, De Braekeleer J. Clinical efficacy of a herpes simplex subunit vaccine. J Med Virol. 1985;16:137-145.
146. Kutinova L, Benda R, Kalos Z, et al. Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine. 1988;6:223-228.
147. Koelle DM, Schomogyi M, Corey L. Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection. J Infect Dis. 2000;182:662-670.
148. Ashley RL, Corey L, Dalessio J, et al. Protein-specific cervical antibody responses to primary genital herpes simplex virus type 2 infections. J Infect Dis. 1994;170:20-26.
149. Ghiasi H, Wechsler SL, Kaiwar R, Nesburn AB, Hofman FM. Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1. J Virol. 1995;69:334-340.
150. Ghiasi H, Cai S, Slanina SM, Perng GC, Nesburn AB, Wechsler SL. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J Infect Dis. 1999;179:1086-1093.
151. Corey L, Wald A. Genital Herpes. In: Holmes KK, P.F.S., Mardh PA, et al. Sexually Transmitted Diseases. New York: McGraw-Hill; 1999:285-312.
152. Ghiasi H, Roopenian DC, Slanina S, Cai S, Nesburn AB, Wechsler SL. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Immunology. 1997;91:430-435.
153. Moore AC, Kong Wp W, Chakrabarti BK, Nabel GJ. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol. 2002;76:243-250.
154. Morrison LA. The Toll of herpes simplex virus infection. Trends Microbiol. 2004;12:353-356.
155. Koelle DM, Liu Z, McClurkan CL, et al. Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci USA. 2003;100:12899-12904.
156. Kwok WW, Gebe JA, Liu A, et al. Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends Immunol. 2001;22:583-588.
157. Lekstrom-Himes JA, Hohman P, Warren T, et al. Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections. J Infect Dis. 1999;179:1077-1085.